製品名:Methyl cyclobutanecarboxylate

IUPAC Name:methyl cyclobutanecarboxylate

CAS番号:765-85-5
分子式:C6H10O2
純度:95%+
カタログ番号:CM344654
分子量:114.14

包装単位 有効在庫 価格(USD) 数量
CM344654-10g in stock Ȁź
CM344654-25g in stock ȎŢNJ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:765-85-5
分子式:C6H10O2
融点:-
SMILESコード:O=C(C1CCC1)OC
密度:
カタログ番号:CM344654
分子量:114.14
沸点:
MDL番号:MFCD00095142
保管方法:

Category Infos

Cyclobutanes
The molecular structure of cyclobutane has four carbon atoms, and its four carbon atoms are not in the same plane, which is the folded conformation of cyclobutane. Cyclobutane itself is not of commercial or biological interest, but more complex derivatives are important in biology and biotechnology. Currently, nine FDA-approved drugs contain the cyclobutane structure. From the perspective of therapeutic areas, cyclobutyl drugs are mainly distributed in popular areas such as tumors, neurological diseases, infectious diseases, endocrine and metabolic diseases.

Column Infos

XRD-0394
XRad Therapeutics announced that the first patient has been dosed in the company’s Phase 1a trial evaluating XRD-0394 in combination with radiation therapy for the treatment of metastatic, locally-advanced or recurrent solid tumors.
XRD-0394, is a first-in-class dual inhibitor of ataxia-telangiectasia mutated (ATM) and DNA-dependent protein kinase (DNA-PK). Initial development efforts are focused on evaluating XRD-0394’s ability to enhance radiation therapy when used in combination. In parallel, the company is exploring the potential benefits of using XRad’s dual kinase inhibitors in combination with targeted radionuclides, immune checkpoint inhibitors, polyadenosine diphosphate-ribose polymerase inhibitors and antibody drug conjugates.

Related Products